Product Name |
CDK4 |
CDK1 |
CDK2 |
CDK3 |
CDK5 |
CDK6 |
CDK7 |
CDK9 |
CDK4 Selectivity |
Purity |
Palbociclib |
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
|
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
Pan Inhibitor
|
≥95.0% |
Palbociclib monohydrochloride |
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
|
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
Pan Inhibitor
|
≥95.0% |
Abemaciclib |
Cdk4/cyclin D1, IC50: 2 nM
|
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
CDK9/cyclinT1, IC50: 57 nM
|
Pan Inhibitor
|
99.69% |
Ribociclib |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.93% |
Abemaciclib methanesulfonate |
Cdk4/cyclin D1, IC50: 2 nM
|
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
CDK9/cyclinT1, IC50: 57 nM
|
Pan Inhibitor
|
≥98.0% |
Flavopiridol |
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.72% |
PF-06873600 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.98% |
Palbociclib isethionate |
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
|
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
Pan Inhibitor
|
99.96% |
SNS-032 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.50% |
AZD-5438 |
cdk4-cyclin D1, IC50: 449 nM
|
cdk1-cyclin B1, IC50: 16 nM
|
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
|
|
|
cdk6-cyclin D3, IC50: 21 nM
|
cdk7-cyclin H, IC50: 821 nM
|
cdk9-cyclin T, IC50: 20 nM
|
Pan Inhibitor
|
99.37% |
AT7519 |
Cdk4/cyclin D1, IC50: 100 nM
|
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
CDK9/Cyclin T, IC50: 10 nM
|
Pan Inhibitor
|
99.40% |
Flavopiridol Hydrochloride |
CDK4/Cyc D1, IC50: 100 nM
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥95.0% |
GSK 3 Inhibitor IX |
Cdk4/cyclin D1, IC50: 10 μM
|
Cdk1/cyclin B, IC50: 320 nM
|
cdk2/cyclin A, IC50: 300 nM
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
Ribociclib succinate |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.52% |
JNJ-7706621 |
Cdk4/cyclin D1, IC50: 253 nM
|
Cdk1/cyclin B, IC50: 9 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
CDK3/Cyclin E, IC50: 58 nM
|
|
CDK6/cyclinD1, IC50: 175 nM
|
|
|
Pan Inhibitor
|
99.96% |
Samuraciclib hydrochloride |
|
|
cdk2/cyclin A, IC50: 578 nM
|
|
CDK5/p35NCK, IC50: 9.4 μM
|
|
CDK7/cyclin H, IC50: 41 nM
|
|
Pan Inhibitor
|
99.98% |
CVT-313 |
Cdk4/cyclin D1, IC50: 215 μM
|
Cdk1/cyclin B, IC50: 4.2 μM
|
cdk2/cyclin A, IC50: 0.5 μM
|
|
|
|
|
|
Pan Inhibitor
|
99.76% |
CGP60474 |
CDK4/cyclin D, IC50: 216 nM
|
CDK1-Cyclin B, IC50: 26 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
|
|
|
CDK7/cyclin H, IC50: 200 nM
|
|
Pan Inhibitor
|
98.70% |
Milciclib |
cyclin D1/CDK4, IC50: 160 nM
|
cyclin B/CDK1, IC50: 398 nM
|
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
|
|
|
|
cyclin H/CDK7, IC50: 150 nM
|
|
Pan Inhibitor
|
99.92% |
BMS-265246 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.28% |
R547 |
|
Cdk1/cyclin B, Ki: 2 nM
Cdk1/cyclin B, IC50: 0.2 nM
|
CDK2/cyclinE, Ki: 3 nM
cdk2/cyclin A, IC50: 0.1 nM
CDK2/cyclinE, IC50: 0.4 nM
|
CDK3/Cyclin E, IC50: 0.8 nM
|
|
cdk6/cyclin D3, IC50: 4 nM
|
CDK7/cyclin H, IC50: 171 nM
|
|
Pan Inhibitor
|
99.66% |
Ribociclib hydrochloride |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.95% |
LDC000067 |
cdk4-cyclin D1, IC50: 9242 nM
|
cdk1-cyclin B1, IC50: 5513 nM
|
cdk2-cyclin A, IC50: 2441 nM
|
|
|
|
|
CDK9- Cyclin T1, IC50: 44 nM
|
Pan Inhibitor
|
98.58% |
Purvalanol A |
cdk4-cyclin D1, IC50: 850 nM
|
cdc2-cyclin B, IC50: 4 nM
|
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
|
|
|
|
|
|
Pan Inhibitor
|
99.11% |
Roniciclib |
CDK4/cyclin D, IC50: 11 nM
|
Cdk1/cyclin B, IC50: 7 nM
|
|
|
|
|
CDK7/Cyclin H/MAT1, IC50: 25 nM
|
CDK9/cyclinT1, IC50: 5 nM
|
Pan Inhibitor
|
98.89% |
Trilaciclib hydrochloride |
Cdk4/cyclin D1, IC50: 1 nM
|
|
|
|
|
cdk6/cyclin D3, IC50: 4 nM
|
|
|
Pan Inhibitor
|
99.24% |
PHA-793887 |
Cdk4/cyclin D1, IC50: 62 nM
|
Cdk1/cyclin B, IC50: 60 nM
|
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
|
|
|
|
CDK7/cyclin H, IC50: 10 nM
|
CDK9/cyclinT1, IC50: 138 nM
|
Pan Inhibitor
|
99.25% |
ON123300 |
Cdk4/cyclin D1, IC50: 3.9 nM
|
|
|
|
|
CDK6/cyclinD1, IC50: 9.82 nM
|
|
|
Pan Inhibitor
|
98.52% |
SU9516 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.83% |
BS-181 |
|
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
Pan Inhibitor
|
98.10% |
FN-1501 |
Cdk4/cyclin D1, IC50: 0.85 nM
|
|
cdk2/cyclin A, IC50: 2.47 nM
|
|
|
CDK6/cyclinD1, IC50: 1.96 nM
|
|
|
Pan Inhibitor
|
98.41% |
Purvalanol B |
Cdk4/cyclin D1, IC50: 10000 nM
|
cdc2/cyclin B, IC50: 6 nM
cyclin dependent kinase 1-cyclinB, IC50: 6 nM
|
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
|
|
|
|
|
|
Pan Inhibitor
|
≥97.0% |
Riviciclib hydrochloride |
cdk4-cyclin D1, IC50: 0.063 μM
|
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
|
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
Pan
|
98.33% |
Abemaciclib metabolite M20 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.24% |
ON-013100 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.23% |
Abemaciclib metabolite M2 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.82% |
AT7519 Hydrochloride |
Cdk4/cyclin D1, IC50: 100 nM
|
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
CDK9/Cyclin T, IC50: 10 nM
|
Pan Inhibitor
|
99.99% |
CDKI-73 |
|
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
|
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
|
|
|
|
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
|
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
|
Pan Inhibitor
|
99.58% |
AMG 925 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.33% |
BS-181 hydrochloride |
|
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
Pan Inhibitor
|
≥99.0% |
MC180295 |
CDK4-Cyclin D, IC50: 112 nM
|
CDK1-Cyclin B, IC50: 138 nM
|
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
|
CDK3-Cyclin E, IC50: 399 nM
|
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
|
cdk6-cyclin D3, IC50: 712 nM
|
CDK7-CycH/MAT1, IC50: 555 nM
|
CDK9- Cyclin T1, IC50: 5 nM
|
Pan Inhibitor
|
98.47% |
Voruciclib hydrochloride |
|
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
|
Pan Inhibitor
|
98.20% |
Lerociclib dihydrochloride |
Cdk4/cyclin D1, IC50: 1 nM
|
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
CDK9/Cyclin T, IC50: 28 nM
|
Pan Inhibitor
|
98.45% |
Ribociclib succinate hydrate |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.96% |
CDK9-IN-7 |
CDK4/cyclin D, IC50: 148 nM
|
|
|
|
|
CDK6/cyclinD, IC50: 145 nM
|
|
CDK9/cyclinT1, IC50: 11 nM
|
Pan Inhibitor
|
99.81% |
BSJ-04-132 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.08% |
BSJ-03-204 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.34% |
Voruciclib |
|
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
|
Pan Inhibitor
|
99.52% |
CAN508 |
Cdk4/cyclin D1, IC50: 13.5 μM
|
Cdk1/cyclin B, IC50: 44 μM
|
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
|
|
|
|
CDK7/cyclin H, IC50: 26 μM
|
CDK9/cyclinT1, IC50: 0.35 μM
|
Pan Inhibitor
|
|
NU6140 |
CDK4-Cyclin D, IC50: 5.5 μM
|
CDK1-Cyclin B, IC50: 6.6 μM
|
cdk2-cyclin A, IC50: 0.41 μM
|
|
|
|
cdk7-cyclin H, IC50: 3.9 μM
|
|
Pan Inhibitor
|
≥99.0% |
CDK4/6-IN-2 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.82% |
NU6102 |
|
Cdk1/cyclin B, IC50: 9.5 nM
|
CDK2/cyclin A3, IC50: 5.4 nM
|
|
|
|
|
|
Pan Inhibitor
|
≥95.0% |
Palbociclib D8 |
Cdk4/cyclin D3, IC50: 9 nM
Cdk4/cyclin D1, IC50: 11 nM
|
|
|
|
|
Cdk6/cyclin D2, IC50: 16 nM
|
|
|
Pan Inhibitor
|
99.84% |
AMG 925 HCl |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.01% |
AT7519 trifluoroacetate |
Cdk4/cyclin D1, IC50: 100 nM
|
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
CDK9/Cyclin T, IC50: 10 nM
|
Pan Inhibitor
|
98.16% |
CDK4/6-IN-3 |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Riviciclib |
cdk4-cyclin D1, IC50: 0.063 μM
|
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
|
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
Pan Inhibitor
|
|
Lerociclib |
Cdk4/cyclin D1, IC50: 1 nM
|
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
CDK9/Cyclin T, IC50: 28 nM
|
Pan Inhibitor
|
|
Nimbolide |
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Indirubin-5-sulfonate |
Cdk4/cyclin D1, IC50: 300 nM
|
Cdk1/cyclin B, IC50: 55 nM
|
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
|
|
|
|
|
|
Pan Inhibitor
|
|
LSN3106729 hydrochloride |
|
|
|
|
|
|
|
|
Inhibitor
|
99.01% |